Benzamide Compounds Useful as Histone Deacetylase Inhibitors
申请人:Andrews David Michael
公开号:US20080269294A1
公开(公告)日:2008-10-30
The invention concerns benzamide compounds of formula (I), wherein R
1
is a C-linked pyrazole ring, which is optionally substituted by one or more groups selected from C
1-4
alkyl, C
3-4
cycloalkyl, C
1-4
alkoxy and C
3-4
cycloalkoxy; or a pharmaceutically acceptable salt or pro-drug form thereof. The invention also concerns processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase (HDAC).
Benzamide compounds useful as histone deacetylase inhibitors
申请人:Astrazeneca AB
公开号:US08207202B2
公开(公告)日:2012-06-26
The invention concerns benzamide compounds of formula (I), wherein R1 is a C-linked pyrazole ring, which is optionally substituted by one or more groups selected from C1-4alkyl, C3-4cycloalkyl, C1-4alkoxy and C3-4cycloalkoxy; or a pharmaceutically acceptable salt or pro-drug form thereof. The invention also concerns processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase (HDAC).
BENZAMIDE COMPOUNDS USEFUL AS HISTONE DEACETYLASE INHIBITORS
申请人:Andrews David Michael
公开号:US20120225907A1
公开(公告)日:2012-09-06
The invention concerns benzamide compounds of formula (I): compound of formula (I):
wherein R
1
is a C-linked pyrazole ring, which is optionally substituted by one or more groups selected from C
1-4
alkyl, C
3-4
cycloalkyl, C
1-4
alkoxy and C
3-4
cycloalkoxy;
or a pharmaceutically acceptable salt or pro-drug form thereof. The invention also concerns processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions, which are sensitive to the inhibition of histone deacetylase (HDAC).